Results from the EMPHASIS-HF trial were used to develop a discrete-event simulation model estimating lifetime direct costs and effects ( life years and quality-adjusted life years ( QALYs ) gained ) of the addition of eplerenone to standard care among patients with chronic systolic HF and mild symptoms .